Justin Kao

Justin is a Partner at Khosla Ventures, and is passionate about supporting entrepreneurs who seek to transform healthcare. His areas of interest include better uses of data to improve healthcare, technologies to increase the efficiency of therapeutic development and patient matching, the intersection of consumerization and care, real world evidence, and precision health.

Prior to Khosla Ventures, Justin was a co-founder and Chief Business Officer at Helix, a leading population genomics company that raised over $320 million from a diverse investor group. Justin led the commercial organization at Helix, including business development, marketing, strategy, clinical, and partnerships, and architected the company’s strategy and partnerships with leading health systems, payers, and life sciences companies. 

Previously, Justin was a Vice President in the healthcare group at Warburg Pincus, a global private equity firm focused on growth investing, where he focused on companies developing and commercializing innovative healthcare technologies. His investments included JHP Pharmaceuticals (acquired by Par Pharmaceuticals), Silk Road Medical (NASDAQ:SILK), Constitution Medical (acquired by Roche Diagnostics), Accriva Diagnostics (acquired by Werfen), Outset Medical (NASDAQ:OM), Singular Bio (acquired by Invitae), and SOC Telemed. Justin started his career at the Boston Consulting Group, where he worked with a variety of companies in the tech and healthcare industries. He also spent time at Onyx Pharmaceuticals, where he played a key role in the acquisition of Proteolix.

Justin holds a B.S. in Chemical Engineering (with distinction) and an M.S. in Bioengineering from Stanford University. He also received a J.D. from Stanford Law School and an M.B.A. from Stanford Graduate School of Business, where he was an Arjay Miller Scholar.